BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31533348)

  • 1. Disseminated Well-Differentiated Gastro-Entero-Pancreatic Tumors Are Associated with Metabolic Syndrome.
    Santos AP; Castro C; Antunes L; Henrique R; Cardoso MH; Monteiro MP
    J Clin Med; 2019 Sep; 8(9):. PubMed ID: 31533348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visceral Obesity Is Associated with Shorter Progression-Free Survival in Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Neoplasia.
    Santos AP; Rodrigues J; Henrique R; Cardoso MH; Monteiro MP
    J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
    Santos AP; Santos AC; Castro C; Raposo L; Pereira SS; Torres I; Henrique R; Cardoso H; Monteiro MP
    Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30150555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors.
    Barrea L; Muscogiuri G; Modica R; Altieri B; Pugliese G; Minotta R; Faggiano A; Colao A; Savastano S
    Front Endocrinol (Lausanne); 2021; 12():649496. PubMed ID: 33815296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher IL-6 peri-tumoural expression is associated with gastro-intestinal neuroendocrine tumour progression.
    Pereira SS; Pereira R; Santos AP; Costa MM; Morais T; Sampaio P; Machado B; Afonso LP; Henrique R; Monteiro MP
    Pathology; 2019 Oct; 51(6):593-599. PubMed ID: 31466863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1.
    Peracchi M; Conte D; Gebbia C; Penati C; Pizzinelli S; Arosio M; Corbetta S; Spada A
    Eur J Endocrinol; 2003 Jan; 148(1):39-43. PubMed ID: 12534356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Glasgow Prognostic Score Predicts Survival Outcomes in Neuroendocrine Neoplasms of the Gastro-Entero-Pancreatic (GEP-NEN) System.
    Gebauer N; Ziehm M; Gebauer J; Riecke A; Meyhöfer S; Kulemann B; von Bubnoff N; Steinestel K; Bauer A; Witte HM
    Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
    Tang LH; Basturk O; Sue JJ; Klimstra DS
    Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronotype: what role in the context of gastroenteropancreatic neuroendocrine tumors?
    Barrea L; Muscogiuri G; Pugliese G; Modica R; Laudisio D; Aprano S; Faggiano A; Colao A; Savastano S
    J Transl Med; 2021 Jul; 19(1):324. PubMed ID: 34330303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
    Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
    Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
    Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
    Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract.
    Goretzki PE; Mogl MT; Akca A; Pratschke J
    Rev Endocr Metab Disord; 2018 Jun; 19(2):169-178. PubMed ID: 30280290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness.
    Barrea L; Altieri B; Muscogiuri G; Laudisio D; Annunziata G; Colao A; Faggiano A; Savastano S
    Nutrients; 2018 Dec; 10(12):. PubMed ID: 30513732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glyoxalase 1 copy number variation in patients with well differentiated gastro-entero-pancreatic neuroendocrine tumours (GEP-NET).
    Xue M; Shafie A; Qaiser T; Rajpoot NM; Kaltsas G; James S; Gopalakrishnan K; Fisk A; Dimitriadis GK; Grammatopoulos DK; Rabbani N; Thornalley PJ; Weickert MO
    Oncotarget; 2017 Sep; 8(44):76961-76973. PubMed ID: 29100361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Genomic Profiling and Chemotherapy Outcomes in Grade 3 Gastro-Entero-Pancreatic Neuroendocrine Tumors (G3 GEP-NET).
    Lamberti G; Prinzi N; Bongiovanni A; Torniai M; Andrini E; Biase D; Malvi D; Mosca M; Berardi R; Ibrahim T; Pusceddu S; Campana D
    Diagnostics (Basel); 2023 Apr; 13(9):. PubMed ID: 37174986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.
    Faggiano A; Carratù AC; Guadagno E; Tafuto S; Tatangelo F; Riccardi F; Mocerino C; Palmieri G; Damiano V; Siciliano R; Leo S; Mauro A; Tozzi LF; Battista C; De Rosa G; Colao A
    Oncotarget; 2016 Feb; 7(5):5538-47. PubMed ID: 26701729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.
    Milione M; Miceli R; Barretta F; Pellegrinelli A; Spaggiari P; Tagliabue G; Centonze G; Paolino C; Mangogna A; Kankava K; Pusceddu S; Giacomelli L; Corti A; Cotsoglou C; Mazzaferro V; Sozzi G; de Braud F; Pruneri G; Anichini A
    J Pathol Clin Res; 2019 Oct; 5(4):217-226. PubMed ID: 31136102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proposal for a New Diagnostic Histopathological Approach in the Evaluation of Ki-67 in GEP-NETs.
    Faviana P; Boldrini L; Gentile C; Erba PA; Sammarco E; Bartoli F; Esposito E; Galli L; Lippolis PV; Bardi M
    Diagnostics (Basel); 2022 Aug; 12(8):. PubMed ID: 36010311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system.
    Arnold CN; Sosnowski A; Schmitt-Gräff A; Arnold R; Blum HE
    Int J Cancer; 2007 May; 120(10):2157-64. PubMed ID: 17278096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.